Mechanism and clinical significance of prostaglandin-induced iris pigmentation

Johan W. Stjernschantz, Daniel Albert, Dan Ning Hu, Filippo Drago, Per J. Wistrand

Research output: Contribution to journalReview article

87 Citations (Scopus)

Abstract

The new glaucoma drugs latanoprost, isopropyl unoprostone, travoprost, and bimatoprost cause increased pigmentation of the iris in some patients. The purpose of the present article is to survey the available preclinical and clinical data on prostaglandin-induced iris pigmentation and to assess the phenomenon from a clinical perspective. Most of the data have been obtained with latanoprost, and it appears that there is a predisposition to latanoprost-induced iris pigmentation in individuals with hazel or heterochromic eye color. As latanoprost and travoprost are selective agonists for the prostaglandin F receptor, it is likely that the phenomenon is mediated by this receptor. Several studies indicate that latanoprost stimulates melanogenesis in iridial melanocytes, and transcription of the tyrosinase gene is upregulated. The safety aspects of latanoprost-induced iris pigmentation have been addressed in histopathologic studies, and no evidence of harmful consequences of the side effect has been found. Although a final assessment of the clinical significance of prostaglandin-induced iris pigmentation currently is impossible to make, it appears that the only clear-cut disadvantage is a potential heterochromia between the eyes in unilaterally treated patients because the heterochromia is likely to be permanent, or very slowly reversible.

Original languageEnglish (US)
JournalSurvey of Ophthalmology
Volume47
Issue number4 SUPPL. 1
DOIs
StatePublished - Aug 1 2002
Externally publishedYes

Fingerprint

latanoprost
Pigmentation
Iris
Prostaglandins
Eye Color
Monophenol Monooxygenase
Melanocytes
Glaucoma

Keywords

  • Bimatoprost
  • Eye color
  • Glaucoma
  • Heterochromia
  • Iridial melanocytes
  • Isopropyl unoprostone
  • Latanoprost
  • Melanogenesis
  • Prostaglandin-induced iris pigmentation
  • Travoprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mechanism and clinical significance of prostaglandin-induced iris pigmentation. / Stjernschantz, Johan W.; Albert, Daniel; Hu, Dan Ning; Drago, Filippo; Wistrand, Per J.

In: Survey of Ophthalmology, Vol. 47, No. 4 SUPPL. 1, 01.08.2002.

Research output: Contribution to journalReview article

Stjernschantz, Johan W. ; Albert, Daniel ; Hu, Dan Ning ; Drago, Filippo ; Wistrand, Per J. / Mechanism and clinical significance of prostaglandin-induced iris pigmentation. In: Survey of Ophthalmology. 2002 ; Vol. 47, No. 4 SUPPL. 1.
@article{3c30672eedf9416d9d6e36fe7ed89d18,
title = "Mechanism and clinical significance of prostaglandin-induced iris pigmentation",
abstract = "The new glaucoma drugs latanoprost, isopropyl unoprostone, travoprost, and bimatoprost cause increased pigmentation of the iris in some patients. The purpose of the present article is to survey the available preclinical and clinical data on prostaglandin-induced iris pigmentation and to assess the phenomenon from a clinical perspective. Most of the data have been obtained with latanoprost, and it appears that there is a predisposition to latanoprost-induced iris pigmentation in individuals with hazel or heterochromic eye color. As latanoprost and travoprost are selective agonists for the prostaglandin F2α receptor, it is likely that the phenomenon is mediated by this receptor. Several studies indicate that latanoprost stimulates melanogenesis in iridial melanocytes, and transcription of the tyrosinase gene is upregulated. The safety aspects of latanoprost-induced iris pigmentation have been addressed in histopathologic studies, and no evidence of harmful consequences of the side effect has been found. Although a final assessment of the clinical significance of prostaglandin-induced iris pigmentation currently is impossible to make, it appears that the only clear-cut disadvantage is a potential heterochromia between the eyes in unilaterally treated patients because the heterochromia is likely to be permanent, or very slowly reversible.",
keywords = "Bimatoprost, Eye color, Glaucoma, Heterochromia, Iridial melanocytes, Isopropyl unoprostone, Latanoprost, Melanogenesis, Prostaglandin-induced iris pigmentation, Travoprost",
author = "Stjernschantz, {Johan W.} and Daniel Albert and Hu, {Dan Ning} and Filippo Drago and Wistrand, {Per J.}",
year = "2002",
month = "8",
day = "1",
doi = "10.1016/S0039-6257(02)00292-8",
language = "English (US)",
volume = "47",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Mechanism and clinical significance of prostaglandin-induced iris pigmentation

AU - Stjernschantz, Johan W.

AU - Albert, Daniel

AU - Hu, Dan Ning

AU - Drago, Filippo

AU - Wistrand, Per J.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - The new glaucoma drugs latanoprost, isopropyl unoprostone, travoprost, and bimatoprost cause increased pigmentation of the iris in some patients. The purpose of the present article is to survey the available preclinical and clinical data on prostaglandin-induced iris pigmentation and to assess the phenomenon from a clinical perspective. Most of the data have been obtained with latanoprost, and it appears that there is a predisposition to latanoprost-induced iris pigmentation in individuals with hazel or heterochromic eye color. As latanoprost and travoprost are selective agonists for the prostaglandin F2α receptor, it is likely that the phenomenon is mediated by this receptor. Several studies indicate that latanoprost stimulates melanogenesis in iridial melanocytes, and transcription of the tyrosinase gene is upregulated. The safety aspects of latanoprost-induced iris pigmentation have been addressed in histopathologic studies, and no evidence of harmful consequences of the side effect has been found. Although a final assessment of the clinical significance of prostaglandin-induced iris pigmentation currently is impossible to make, it appears that the only clear-cut disadvantage is a potential heterochromia between the eyes in unilaterally treated patients because the heterochromia is likely to be permanent, or very slowly reversible.

AB - The new glaucoma drugs latanoprost, isopropyl unoprostone, travoprost, and bimatoprost cause increased pigmentation of the iris in some patients. The purpose of the present article is to survey the available preclinical and clinical data on prostaglandin-induced iris pigmentation and to assess the phenomenon from a clinical perspective. Most of the data have been obtained with latanoprost, and it appears that there is a predisposition to latanoprost-induced iris pigmentation in individuals with hazel or heterochromic eye color. As latanoprost and travoprost are selective agonists for the prostaglandin F2α receptor, it is likely that the phenomenon is mediated by this receptor. Several studies indicate that latanoprost stimulates melanogenesis in iridial melanocytes, and transcription of the tyrosinase gene is upregulated. The safety aspects of latanoprost-induced iris pigmentation have been addressed in histopathologic studies, and no evidence of harmful consequences of the side effect has been found. Although a final assessment of the clinical significance of prostaglandin-induced iris pigmentation currently is impossible to make, it appears that the only clear-cut disadvantage is a potential heterochromia between the eyes in unilaterally treated patients because the heterochromia is likely to be permanent, or very slowly reversible.

KW - Bimatoprost

KW - Eye color

KW - Glaucoma

KW - Heterochromia

KW - Iridial melanocytes

KW - Isopropyl unoprostone

KW - Latanoprost

KW - Melanogenesis

KW - Prostaglandin-induced iris pigmentation

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=0036669681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036669681&partnerID=8YFLogxK

U2 - 10.1016/S0039-6257(02)00292-8

DO - 10.1016/S0039-6257(02)00292-8

M3 - Review article

VL - 47

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 4 SUPPL. 1

ER -